Phase Forward (PFWD) Signs Multi-Yr, Multi-Million Dollar Contract with GlaxoSmithKline (GSK)
Phase Forward (NASDAQ: PFWD) today announced that GlaxoSmithKline (NYSE: GSK) has signed multi-year, multi-million dollar contracts covering Licensing and Study Support Services. GSK and Phase Forward also have a multi-year agreement in place for hosting services. Under the terms of the newly signed agreements, GSK will continue to utilize Phase Forward's InForm(TM) Integrated Trial Management solution. Since 2004, GSK has initiated nearly 600 clinical trials with Phase Forward's InForm electronic data capture solution and utilizing Phase Forward's hosting and study support services.
You May Also Be Interested In
- Basilea participates in public-private collaboration to tackle antibiotic resistance
- Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
